Prof. Ying Cheng 程颖
Chief Physician, Professor
Department of Medical Oncology, Jilin Cancer Hospital, Changchun
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for lung cancer, breast cancer, malignant lymphoma, gastrointestinal tumors, nasopharyngeal carcinoma, and seminoma.
Dr. Cheng graduated from Bethune Medical University in 1986 and became a Chief Physician in 2001. With 26 years in medical oncology, Dr. Cheng serves as Director of Jilin Cancer Hospital. Research focuses on lung cancer, breast cancer, lymphoma, and immunotherapy. Dr. Cheng participated in writing national lung cancer guidelines and 90 clinical trials, including 25 international multi-center studies.
Professional roles
- Member, Chinese Medical Association
- Vice Chair, Committee on Clinical Chemotherapy, China Anti-Cancer Association (4th Committee)
- Chair, Small Cell Lung Cancer Professional Committee, Chinese Society of Clinical Oncology (CSCO) (2010)
Name order: in Chinese the family name comes first (Cheng Ying). Papers usually list the name as Ying Cheng or Cheng Y.
Selected publications
322 papers on PubMed matched by name and affiliation; 53 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ann Med, 2026 (senior author): Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboring SMARCA4 mutations. PubMed 41593906
- Lancet Oncol, 2026 (senior author): Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial. PubMed 41539318
- Chin Med J (Engl), 2026 (senior author): Targeting XPO1: A new perspective for malignant solid tumor especially small cell lung cancer. PubMed 40719308
- Curr Med Res Opin, 2025 (first author): Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage small-cell lung cancer: patient-reported outcomes in the RATIONALE-312 trial. PubMed 41614649
- Biomed Pharmacother, 2025 (senior author): A clinically translatable 2.5D lung adenocarcinoma organoid platform derived from malignant pleural effusions for precision drug screening and tumor-immune-stromal modeling. PubMed 41175595
- Cell Death Dis, 2025 (senior author): Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming. PubMed 41184283
- JTO Clin Res Rep, 2025 (senior author): First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion-Positive NSCLC: A LIBRETTO-431 Subgroup Analysis. PubMed 40980186
- Transl Lung Cancer Res, 2025 (senior author): The pathogenic mutations in smokers with non-small cell lung cancer: a next-generation sequencing study. PubMed 41132982
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion